New inhaled treatment for children with inherited heart conditions
The project
The project aims to develop a new, non-invasive treatment for children with inherited heart conditions such as hypertrophic cardiomyopathy (HCM). These conditions can cause the heart muscle to thicken, leading to serious health problems from a young age.
Researchers at Curtin are developing a new approach that uses a nebuliser (similar to those used for asthma) to deliver medicine directly to the heart. The treatment uses tiny particles (nanoparticles) to carry genetic medicines designed to help restore normal heart function.
The goal of this research is to create a safer, needle-free treatment option that can be used repeatedly and more comfortably by children and their families.
The involvement opportunity
The research team is looking for 2 consumers to join them. Consumers will:
- Provide feedback on the acceptability and useability of an inhaled treatment for children
- Share perspectives on how families manage long-term treatment
- Help guide how research outcomes are communicated to the community
- Contribute to ensuring the research aligns with patient and family needs
Skills and experience
The research team are looking for people who:
- Have lived experience as a parent, carer, or family member of a child with a heart condition (such as HCM or similar conditions), or
- Have experience supporting children with chronic health considtions
- Live in WA
Other information
Initially, there will be one meeting (1 hour) held online in late April/early May. This discussion will inform a grant application for funding for the project. If the application is successful, there will be an opportunity for ongoing involvement (approximately 2-3 meetings per year).
- An honorarium payment of $37.50/hour will be offered
Applications close 20 April 2026.